Report cover image

Global Rheumatic Disorders Drug Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 195 Pages
SKU # APRC20557183

Description

Summary

According to APO Research, the global Rheumatic Disorders Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Rheumatic Disorders Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Rheumatic Disorders Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Rheumatic Disorders Drug market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Rheumatic Disorders Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Rheumatic Disorders Drug market include Bristol-Myers Squibb, AbbVie, Amgen, Pfizer, Eli Lilly, Roche, Novartis and Johnson & Johnson, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Rheumatic Disorders Drug, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Rheumatic Disorders Drug, also provides the value of main regions and countries. Of the upcoming market potential for Rheumatic Disorders Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Rheumatic Disorders Drug revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Rheumatic Disorders Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Rheumatic Disorders Drug company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Rheumatic Disorders Drug Segment by Company

Bristol-Myers Squibb
AbbVie
Amgen
Pfizer
Eli Lilly
Roche
Novartis
Johnson & Johnson
Rheumatic Disorders Drug Segment by Type

Acting on Interleukins and Interleukin Receptors
Acting on Protein Kinases
Acting on Hormones and Hormone Receptors
Acting on Cell Surface Antigens
Acting on Tumor Necrosis Factor-Alpha
Others
Rheumatic Disorders Drug Segment by Application

Psoriatic Arthritis
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Osteoporosis
Osteoarthritis
Others
Rheumatic Disorders Drug Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Rheumatic Disorders Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Rheumatic Disorders Drug key companies, revenue, market share, and recent developments.
3. To split the Rheumatic Disorders Drug breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Rheumatic Disorders Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Rheumatic Disorders Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Rheumatic Disorders Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rheumatic Disorders Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rheumatic Disorders Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rheumatic Disorders Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Rheumatic Disorders Drug industry.
Chapter 3: Detailed analysis of Rheumatic Disorders Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Rheumatic Disorders Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Rheumatic Disorders Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Rheumatic Disorders Drug Market Size, 2020 VS 2024 VS 2031
1.3 Global Rheumatic Disorders Drug Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Rheumatic Disorders Drug Market Dynamics
2.1 Rheumatic Disorders Drug Industry Trends
2.2 Rheumatic Disorders Drug Industry Drivers
2.3 Rheumatic Disorders Drug Industry Opportunities and Challenges
2.4 Rheumatic Disorders Drug Industry Restraints
3 Rheumatic Disorders Drug Market by Company
3.1 Global Rheumatic Disorders Drug Company Revenue Ranking in 2024
3.2 Global Rheumatic Disorders Drug Revenue by Company (2020-2025)
3.3 Global Rheumatic Disorders Drug Company Ranking (2023-2025)
3.4 Global Rheumatic Disorders Drug Company Manufacturing Base and Headquarters
3.5 Global Rheumatic Disorders Drug Company Product Type and Application
3.6 Global Rheumatic Disorders Drug Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Rheumatic Disorders Drug Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Rheumatic Disorders Drug Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Rheumatic Disorders Drug Market by Type
4.1 Rheumatic Disorders Drug Type Introduction
4.1.1 Acting on Interleukins and Interleukin Receptors
4.1.2 Acting on Protein Kinases
4.1.3 Acting on Hormones and Hormone Receptors
4.1.4 Acting on Cell Surface Antigens
4.1.5 Acting on Tumor Necrosis Factor-Alpha
4.1.6 Others
4.2 Global Rheumatic Disorders Drug Sales Value by Type
4.2.1 Global Rheumatic Disorders Drug Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Rheumatic Disorders Drug Sales Value by Type (2020-2031)
4.2.3 Global Rheumatic Disorders Drug Sales Value Share by Type (2020-2031)
5 Rheumatic Disorders Drug Market by Application
5.1 Rheumatic Disorders Drug Application Introduction
5.1.1 Psoriatic Arthritis
5.1.2 Systemic Lupus Erythematosus
5.1.3 Rheumatoid Arthritis
5.1.4 Osteoporosis
5.1.5 Osteoarthritis
5.1.6 Others
5.2 Global Rheumatic Disorders Drug Sales Value by Application
5.2.1 Global Rheumatic Disorders Drug Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Rheumatic Disorders Drug Sales Value by Application (2020-2031)
5.2.3 Global Rheumatic Disorders Drug Sales Value Share by Application (2020-2031)
6 Rheumatic Disorders Drug Regional Value Analysis
6.1 Global Rheumatic Disorders Drug Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Rheumatic Disorders Drug Sales Value by Region (2020-2031)
6.2.1 Global Rheumatic Disorders Drug Sales Value by Region: 2020-2025
6.2.2 Global Rheumatic Disorders Drug Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Rheumatic Disorders Drug Sales Value (2020-2031)
6.3.2 North America Rheumatic Disorders Drug Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Rheumatic Disorders Drug Sales Value (2020-2031)
6.4.2 Europe Rheumatic Disorders Drug Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Rheumatic Disorders Drug Sales Value (2020-2031)
6.5.2 Asia-Pacific Rheumatic Disorders Drug Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Rheumatic Disorders Drug Sales Value (2020-2031)
6.6.2 South America Rheumatic Disorders Drug Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Rheumatic Disorders Drug Sales Value (2020-2031)
6.7.2 Middle East & Africa Rheumatic Disorders Drug Sales Value Share by Country, 2024 VS 2031
7 Rheumatic Disorders Drug Country-level Value Analysis
7.1 Global Rheumatic Disorders Drug Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Rheumatic Disorders Drug Sales Value by Country (2020-2031)
7.2.1 Global Rheumatic Disorders Drug Sales Value by Country (2020-2025)
7.2.2 Global Rheumatic Disorders Drug Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.3.2 USA Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.4.2 Canada Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.6.2 Germany Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.7.2 France Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.7.3 France Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.9.2 Italy Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.10.2 Spain Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.11.2 Russia Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.14.2 China Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.14.3 China Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.15.2 Japan Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.17.2 India Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.17.3 India Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.18.2 Australia Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.22.2 Chile Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.24.2 Peru Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.26.2 Israel Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.27.2 UAE Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.29.2 Iran Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Rheumatic Disorders Drug Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Rheumatic Disorders Drug Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Rheumatic Disorders Drug Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Bristol-Myers Squibb
8.1.1 Bristol-Myers Squibb Comapny Information
8.1.2 Bristol-Myers Squibb Business Overview
8.1.3 Bristol-Myers Squibb Rheumatic Disorders Drug Revenue and Gross Margin (2020-2025)
8.1.4 Bristol-Myers Squibb Rheumatic Disorders Drug Product Portfolio
8.1.5 Bristol-Myers Squibb Recent Developments
8.2 AbbVie
8.2.1 AbbVie Comapny Information
8.2.2 AbbVie Business Overview
8.2.3 AbbVie Rheumatic Disorders Drug Revenue and Gross Margin (2020-2025)
8.2.4 AbbVie Rheumatic Disorders Drug Product Portfolio
8.2.5 AbbVie Recent Developments
8.3 Amgen
8.3.1 Amgen Comapny Information
8.3.2 Amgen Business Overview
8.3.3 Amgen Rheumatic Disorders Drug Revenue and Gross Margin (2020-2025)
8.3.4 Amgen Rheumatic Disorders Drug Product Portfolio
8.3.5 Amgen Recent Developments
8.4 Pfizer
8.4.1 Pfizer Comapny Information
8.4.2 Pfizer Business Overview
8.4.3 Pfizer Rheumatic Disorders Drug Revenue and Gross Margin (2020-2025)
8.4.4 Pfizer Rheumatic Disorders Drug Product Portfolio
8.4.5 Pfizer Recent Developments
8.5 Eli Lilly
8.5.1 Eli Lilly Comapny Information
8.5.2 Eli Lilly Business Overview
8.5.3 Eli Lilly Rheumatic Disorders Drug Revenue and Gross Margin (2020-2025)
8.5.4 Eli Lilly Rheumatic Disorders Drug Product Portfolio
8.5.5 Eli Lilly Recent Developments
8.6 Roche
8.6.1 Roche Comapny Information
8.6.2 Roche Business Overview
8.6.3 Roche Rheumatic Disorders Drug Revenue and Gross Margin (2020-2025)
8.6.4 Roche Rheumatic Disorders Drug Product Portfolio
8.6.5 Roche Recent Developments
8.7 Novartis
8.7.1 Novartis Comapny Information
8.7.2 Novartis Business Overview
8.7.3 Novartis Rheumatic Disorders Drug Revenue and Gross Margin (2020-2025)
8.7.4 Novartis Rheumatic Disorders Drug Product Portfolio
8.7.5 Novartis Recent Developments
8.8 Johnson & Johnson
8.8.1 Johnson & Johnson Comapny Information
8.8.2 Johnson & Johnson Business Overview
8.8.3 Johnson & Johnson Rheumatic Disorders Drug Revenue and Gross Margin (2020-2025)
8.8.4 Johnson & Johnson Rheumatic Disorders Drug Product Portfolio
8.8.5 Johnson & Johnson Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.